Biogen (BIIB) Tops Q3 EPS by 61c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Stocks fall as higher oil prices, Treasury yields weigh
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
Biogen Reports Quarterly Revenues of $3.1 Billion
October 24, 2017 6:59 AM EDTTotal revenues grew 4% or 13% excluding hemophilia revenues*
GAAP diluted EPS rise 23%; Non-GAAP diluted EPS rise 22%
Company advances its strategic priorities
Company restructures collaboration arrangements with Eisai and Neurimmune to improve long-term value of aducanumab
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Biogen Inc. (NASDAQ: BIIB) today reported third quarter 2017 financial results, including:
Total revenues of $3.1 billion, a 4% increase versus the prior year or a 13% increase excluding hemophilia revenues*. Multiple sclerosis (MS) revenues, including approximately $65... More